Ovarian cancer treatment targeting angiogenesis and immune tolerance

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462606
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Jichi Medical University
• Principal Investigator: Saga Yasushi 自治医科大学, 医学部, 准教授 (70360071)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: VASH1 / VASH2 / VEGF / PDGF / NK4 / IDO / c-Met / AKT

Outline of Final Research Achievements

・VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF-producing ovarian cancer cells, but also in high PDGF-producing ovarian cancer cells, reduced their peritoneal dissemination and ascites, and prolonged host survival. These results suggest that VASH1 is an effective treatment for ovarian cancer.
・NK4 can inhibit ovarian cancer growth in vivo by inhibition of IDO expression via the c-Met-PI3K-AKT signaling pathway. These results suggest that NK4 represents a potentially useful immunotherapeueutic anticancer agent for ovarian cancer.

Free Research Field

婦人科腫瘍